Related Experiment Video
Updated: Jan 31, 2026
Subcutaneous Infection of Methicillin Resistant Staphylococcus Aureus MRSA
Published on: February 9, 2011
An integrated subtractive genomics and immunoinformatic approach for designing a multi-epitope peptide vaccine
Nandha Kumar Subramani1, Subhashree Venugopal2, Anand Prem Rajan1
1Department of Bio Medical Sciences, School of Bio Science and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India.
Introduction:
MRSA is a multi-drug-resistant bacteria responsible for severe infections that has become a major health concern. Due to constraints of traditional methods, there is a need for developing a new approach to prevent the MRSA-related infections by targeting key pathogens.
Methods:
Initially, the subtractive genomics was applied to the MRSA proteome to identify non-homologous, essential, and virulence targets using comparative BLAST-based screening. Further, immunoinformatic tools were employed for B- and T-cell epitope prediction and vaccine construction with appropriate adjuvants and linkers, followed by immune simulation and molecular docking with immune receptors.
Results:
Comparative metabolic pathway analysis identified 294 MRSA pathway proteins, with acetolactate synthase (ALS) as a non-homologous, essential, and virulent protein that is involved in the branched amino acid biosynthesis pathway. The constructed ALS vaccine consists of 3 B-cell and 19 T-cell epitopes exhibited stable immunological features with 97.55% global population coverage. Molecular docking revealed that ALS exhibited a superior binding affinity with the TLR4 receptor (-1,438.7 kcal/mol) than the TLR2 receptor (-1,103.5 kcal/mol), which was further confirmed by high structural stability and compactness analysis. Immune simulations also exhibited elevated IgM, IgG subtypes, and cytokine productions, suggesting a robust humoral and cellular immunity.
Discussion:
Identified ALS highlights its biological relevance in MRSA survival. The stability predictions with TLR4 suggested effective activation of innate immunity that may enhance antigen presentation and downstream adaptive immunity. The validation of the ALS vaccine's safety and immunogenicity further requires comprehensive in vitro and in vivo examinations.
Conclusion:
Thus, ALS is recognized as a promising MRSA vaccine candidate and has the potential to activate immune responses effectively.
Insights
A novel vaccine targeting acetolactate synthase (ALS) shows promise for preventing Methicillin-resistant Staphylococcus aureus (MRSA) infections. This computational study identified ALS as a key target, demonstrating its potential to elicit a robust immune response against MRSA.
Area of Science:
- Microbiology
- Immunology
- Vaccine Development
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) poses a significant global health threat due to its multi-drug resistance.
- Traditional methods for combating MRSA infections are limited, necessitating novel therapeutic strategies.
Purpose of the Study:
- To identify and characterize potential vaccine targets against MRSA using subtractive genomics and immunoinformatics.
- To design and computationally evaluate a vaccine candidate targeting a key MRSA protein.
Main Methods:
- Subtractive genomics and comparative BLAST screening to identify MRSA-specific essential and virulence targets.
- Immunoinformatic tools for B- and T-cell epitope prediction and vaccine construct design.
- Molecular docking and immune simulations to assess vaccine-host interactions and immune response.
Main Results:
- Acetolactate synthase (ALS) was identified as a non-homologous, essential, and virulent protein in MRSA.
- A multi-epitope vaccine construct targeting ALS demonstrated high global population coverage (97.55%).
- Molecular docking showed strong binding affinity of ALS to TLR4, and immune simulations predicted a robust humoral and cellular immune response.
Conclusions:
- ALS is a promising vaccine candidate for MRSA, capable of activating innate and adaptive immunity.
- Further in vitro and in vivo studies are required to validate the safety and immunogenicity of the ALS vaccine.
More Related Videos
Related Concept Videos
01:14Design Example: Resistive Touchscreen
When a user touches the screen, the two layers make contact at a specific point known as the touchpoint. This contact reduces the resistance between...
01:51Vaccinations
01:28Dosage Regimens: Designs and Approaches
02:02Genomics
02:43Peptide Bonds
02:01Group Design